101. Novel inflammatory CSF biomarkers strongly predict medial temporal atrophy and cognitive decline in Alzheimer’s disease
- Author
-
Auriel A. Willette
- Subjects
Oncology ,medicine.medical_specialty ,Pathology ,Endocrine and Autonomic Systems ,Immunology ,Disease ,medicine.disease ,Temporal lobe ,Behavioral Neuroscience ,Cerebrospinal fluid ,Atrophy ,Neuroimaging ,Internal medicine ,medicine ,Biomarker (medicine) ,Cognitive decline ,Psychology ,Neuroinflammation - Abstract
Background Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by rapid medial temporal lobe (MTL) atrophy and memory loss. These effects are partly induced by chronic neuroinflammation. No study has examined which neuroinflammatory biomarkers in cerebrospinal fluid (CSF), differ most across the AD spectrum and best predict MTL atrophy and memory decline. Methods 287 AD Neuroimaging Initiative (ADNI) participants were assessed. In baseline CSF, nine candidate biomarkers were available in > 90% of participants using mass spectrometry multiplex data (Complement 3; Alpha-1-antitrypsin; CD14; Interleukin-18; YPL-40; Osteopontin; CRP; neuronal pentraxin 1, or NPTX1; NPTX2). MTL atrophy and memory performance were assessed over 24 months. Stepwise regression selected biomarkers that best distinguished non-AD ( n = 86), prodromal AD ( n = 135), and AD ( n = 66), as well as atrophy by 24 months. Linear mixed models regressed selected biomarkers against atrophy and memory performance over time. Results YPL-40 and NPTX2 were selected, which are respectively biomarkers of microglial activation and neuronal inflammatory regulation and synaptogenesis. AD versus non-AD participants had significantly more YPL-40 and less NPTX2. Biomarker ∗ Time interactions showed higher NPTX2 predicted less atrophy ( R 2 = 0.294 ) and higher memory factor scores ( R 2 = 0.560 ) by month 24. Higher YPL-40 modestly predicted more atrophy ( R 2 = 0.059 ) and lower memory factor scores ( R 2 = 0.040 ) by month 24. Conclusions NPTX2 is lower in AD and surprisingly predicts lower atrophy and memory decline. NPTX2 may be a protective factor inhibiting chronic neuroinflammation.
- Published
- 2015